As cancer treatments improve and death rates decline, more patients survive who are at risk of becoming addicted to pain medications they were prescribed to treat their cancer-related pain, explained Merrill Norton, PharmD, NCAC II, CCS, CCDP-D, of the University of Georgia.
Positive quality interventions are part of a nationwide effort to standardize and improve oncology dispensing practices. They are best practices that are meant to be highly specific to a drug and help pharmacies and clinicians ensure that a patient-centric model exists, explained speakers during a workshop at National Community Oncology Dispensing Association (NCODA) Spring Forum 2018.
Being proactive about identifying potential financial burdens and preparing patients who have a disease for the costs of their treatment helps to ensure that patients will be adherent to their medication and have the best possible outcomes, according to a panel of providers at the Cost-Sharing Roundtable, co-hosted by the Patient Access Network Foundation and The American Journal of Managed Care®.
Coverage from the National Community Oncology Dispensing Association Spring Forum 2018.
Since 2000, the number of patients undergoing gender-affirming surgery who identified as self-payers decreased. From 2012-2013 to 2014, coverage by Medicare and Medicaid of gender-affirming surgeries increased 3-fold.
State variations in chronic obstructive pulmonary disease (COPD) outcomes suggest that the condition is more common in large rural areas compared with metropolitan areas, according to the Morbidity and Mortality Weekly Report from CDC.
New research has found that allogeneic hematopoietic stem cell transplantation is just as effective in patients with non-Hodgkin lymphoma who are age 65 and older as it is in patients between the ages of 55 and 64.
Clinical and policy decisions made using early trial results could be misguided, according to a study that found early results in chronic disease trials are often exaggerated compared with findings in subsequent trials.
Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a new study published in Annals of Internal Medicine.
Long-term use of inhaled corticosteroids, which are widely used to treat chronic obstructive pulmonary disease, are associated with an increased risk of fractures, according to a new study in CHEST.
A new National Bureau of Economic Research working paper identified potential hospital cost shifting and that hospitals penalized by the Hospital Readmission Reduction Program and the Hospital Value-Based Purchasing Program actually had an increase in average payments of 1.5%.
In a new letter published in the February issue of The American Journal of Managed Care®, Martin Makary, MD, a professor of surgery at Johns Hopkins University, and his coauthors assessed price markup variation by hospital and by oncology specialty to better understand the financial hardships patients can face when charges for the same service vary widely across hospitals.
New research published in The Lancet Oncology found that denosumab was noninferior to zoledronic acid for time to skeletal-related events in patients with newly diagnosed multiple myeloma.
FDA has approved apalutamide, the first treatment for nonmetastatic castration-resistant prostate cancer, based on results from a phase 3 study that showed the drug reduced the risk of metastasis or death by 72% and improved median metastasis-free survival by more than 2 years.
A new study found that patients with chronic obstructive pulmonary disease with higher symptom burden are worse at self-management, which is an important part of managing the disease.
The addition of daratumumab to standard-of-care regimens used to treat multiple myeloma, such as bortezomib, melphalan, and prednisone, decreased the risk of disease progression or death in newly diagnosed patients who were ineligible for autologous stem-cell transplantation.
Multimorbidity is common in patients with chronic obstructive pulmonary disease (COPD), and is associated with high levels of polypharmacy, which can lead to an increased risk of adverse drug reactions.
After a brief shutdown in the dead of night, the Senate passed a spending bill, which was the result of a deal reached by Republicans and Democrats to fund military and domestic programs for 2 years. The House passed the bill shortly after.
A long-term follow-up analyzing the toxic effects and results from a phase 1 clinical trial of adult patients with relapsed B-cell acute lymphoblastic leukemia (ALL) who were treated with CD19-specific chimeric antigen receptor (CAR) T cells found patients with low disease burden had a longer medial overall survival and a lower incidence of toxicity.
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Replacing the Merit-based Incentive Payment System (MIPS) with a voluntary program should encourage providers to move quicker into more risk-based payment models, according to Travis Broome, vice president for policy at Aledade.
Including pharmacists in a team-based care model to treat patients with chronic pain can help primary care physicians create a plan to safely prescribe opioids to this population.
With adoption of electronic health records around 90%, the Office of the National Coordinator of Health Information Technology is now focusing on increasing usability and interoperability.
Shifting care for patients with chronic obstructive pulmonary disease (COPD) from the hospital to the home reduced hospital readmissions by 64% and emergency department visits by 52%, a Canadian program found.
Every year, central lines are associated with causing blood infections in an estimated 400,000 patients with cancer. However, new research has found that changes in the microbiome may be responsible for some or many of the infections usually attributed to central lines.
The current flu season is already bad, but it hasn’t peaked yet. Here are 5 things about the current flu season and why it has been so harsh.
Kentucky residents have filed a lawsuit against the Trump administration for approving a waiver to add work requirements to the state's Medicaid program.
The FDA has approved a supplemental New Drug Application to add new overall survival (OS) data for carfilzomib (Kyprolis). The label will now show that carfilzomib and dexamethasone reduced the risk of death by 21% and increased OS by 7.6 months compared with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (MM).
Despite years of stability, patients with monoclonal gammopathy of undetermined significance (MGUS) are at risk of progressing to multiple myeloma or another blood cancer, according to a long-term follow-up study published in New England Journal of Medicine. MGUS usually causes no problems, but it is a precursor to cancer.
Five health systems are coming together to form a new nonprofit generic drug company that will addressing rising generic drug costs and drug shortages at hospitals.
